IBDEI0Q8 ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34715,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,34715,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,34716,0)
 ;;=D56.0^^100^1507^21
 ;;^UTILITY(U,$J,358.3,34716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34716,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,34716,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,34716,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,34717,0)
 ;;=D63.1^^100^1507^23
 ;;^UTILITY(U,$J,358.3,34717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34717,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,34717,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,34717,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,34718,0)
 ;;=D63.0^^100^1507^24
 ;;^UTILITY(U,$J,358.3,34718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34718,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,34718,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,34718,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,34719,0)
 ;;=D63.8^^100^1507^22
 ;;^UTILITY(U,$J,358.3,34719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34719,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,34719,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,34719,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,34720,0)
 ;;=C22.3^^100^1507^26
 ;;^UTILITY(U,$J,358.3,34720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34720,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,34720,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,34720,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,34721,0)
 ;;=D61.9^^100^1507^27
 ;;^UTILITY(U,$J,358.3,34721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34721,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,34721,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,34721,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,34722,0)
 ;;=D56.1^^100^1507^29
 ;;^UTILITY(U,$J,358.3,34722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34722,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,34722,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,34722,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,34723,0)
 ;;=C83.79^^100^1507^31
 ;;^UTILITY(U,$J,358.3,34723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34723,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,34723,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,34723,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,34724,0)
 ;;=C83.70^^100^1507^32
 ;;^UTILITY(U,$J,358.3,34724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34724,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,34724,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,34724,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,34725,0)
 ;;=D09.0^^100^1507^39
 ;;^UTILITY(U,$J,358.3,34725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34725,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,34725,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,34725,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,34726,0)
 ;;=D06.9^^100^1507^40
 ;;^UTILITY(U,$J,358.3,34726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34726,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,34726,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,34726,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,34727,0)
 ;;=D06.0^^100^1507^42
 ;;^UTILITY(U,$J,358.3,34727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34727,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,34727,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,34727,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,34728,0)
 ;;=D06.1^^100^1507^43
 ;;^UTILITY(U,$J,358.3,34728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34728,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,34728,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,34728,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,34729,0)
 ;;=D06.7^^100^1507^41
 ;;^UTILITY(U,$J,358.3,34729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34729,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,34729,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,34729,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,34730,0)
 ;;=D04.9^^100^1507^44
 ;;^UTILITY(U,$J,358.3,34730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34730,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,34730,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,34730,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,34731,0)
 ;;=C91.11^^100^1507^47
 ;;^UTILITY(U,$J,358.3,34731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34731,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,34731,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,34731,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,34732,0)
 ;;=C91.10^^100^1507^48
 ;;^UTILITY(U,$J,358.3,34732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34732,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,34732,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,34732,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,34733,0)
 ;;=C92.11^^100^1507^49
 ;;^UTILITY(U,$J,358.3,34733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34733,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,34733,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,34733,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,34734,0)
 ;;=C92.10^^100^1507^50
 ;;^UTILITY(U,$J,358.3,34734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34734,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,34734,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,34734,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,34735,0)
 ;;=D47.1^^100^1507^51
 ;;^UTILITY(U,$J,358.3,34735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34735,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,34735,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,34735,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,34736,0)
 ;;=C82.69^^100^1507^52
 ;;^UTILITY(U,$J,358.3,34736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34736,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,34736,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,34736,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,34737,0)
 ;;=C82.60^^100^1507^53
 ;;^UTILITY(U,$J,358.3,34737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34737,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,34737,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,34737,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,34738,0)
 ;;=D56.2^^100^1507^54
 ;;^UTILITY(U,$J,358.3,34738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34738,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,34738,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,34738,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,34739,0)
 ;;=D75.9^^100^1507^55
 ;;^UTILITY(U,$J,358.3,34739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34739,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,34739,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,34739,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,34740,0)
 ;;=D59.0^^100^1507^58
 ;;^UTILITY(U,$J,358.3,34740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34740,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,34740,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,34740,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,34741,0)
 ;;=D59.2^^100^1507^59
 ;;^UTILITY(U,$J,358.3,34741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34741,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,34741,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,34741,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,34742,0)
 ;;=R59.9^^100^1507^62
 ;;^UTILITY(U,$J,358.3,34742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34742,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,34742,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,34742,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,34743,0)
 ;;=D47.3^^100^1507^63
 ;;^UTILITY(U,$J,358.3,34743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34743,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,34743,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,34743,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,34744,0)
 ;;=C82.09^^100^1507^64
 ;;^UTILITY(U,$J,358.3,34744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34744,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,34744,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,34744,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,34745,0)
 ;;=C82.00^^100^1507^65
 ;;^UTILITY(U,$J,358.3,34745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34745,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,34745,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,34745,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,34746,0)
 ;;=C82.19^^100^1507^66
 ;;^UTILITY(U,$J,358.3,34746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34746,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,34746,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,34746,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,34747,0)
 ;;=C82.10^^100^1507^67
 ;;^UTILITY(U,$J,358.3,34747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34747,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,34747,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,34747,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,34748,0)
 ;;=C82.29^^100^1507^68
 ;;^UTILITY(U,$J,358.3,34748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34748,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,34748,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,34748,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,34749,0)
 ;;=C82.20^^100^1507^69
 ;;^UTILITY(U,$J,358.3,34749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34749,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,34749,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,34749,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,34750,0)
 ;;=C82.39^^100^1507^70
 ;;^UTILITY(U,$J,358.3,34750,1,0)
 ;;=^358.31IA^4^2
